Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: Recent Study of Neurontin

Posted by JohnB on November 6, 1999, at 22:09:08

In reply to Re: Neurontin and sedation, etc., posted by Susan on October 29, 1999, at 11:40:32

Hi. Here's an august '99 published study of neurontin for social phobia, which I copied out of pubmed. sponsor is Parke-Davis, manufacturer of Neurontin. I understand that 3600mg/day was the efficacious dose for social phobia. I also understand that Parke-Davis is planning a follow-up controlled study of all partcipants at 3600mg/day. Apparently, with managed care beginning to only pay for drug prescriptions for FDA approved usage, Parke-Davis has some incentive to get approval of Neurontin for treatment of social phobia. Currently, is only approved use is as an anti-epileptic.

Hope this helps. JohnB. :)

J Clin Psychopharmacol 1999 Aug;19(4):341-8

Treatment of social phobia with gabapentin: a placebo-controlled study.

Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.

A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate the efficacy and safety of gabapentin in relieving the symptoms of social phobia. Sixty-nine patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 900 and 3,600 mg daily in three divided doses) or placebo for 14 weeks. A significant reduction (p < 0.05) in the symptoms of social phobia was observed among patients on gabapentin compared with those on placebo as evaluated by clinician- and patient-rated scales. Results were similar for the intent-to-treat and week-2 completer populations. Adverse events were consistent with the known side effect profile of gabapentin. Dizziness (p = 0.05), dry mouth (p = 0.05), somnolence, nausea, flatulence, and decreased libido occurred at a higher frequency among patients receiving gabapentin than among those receiving placebo. No serious adverse events or deaths were reported. On the basis of these limited data, it seems that gabapentin offers a favorable risk-benefit ratio for the treatment of patients with social phobia. Further studies are required to confirm this effect and to determine whether a dose-response relationship exists.

Publication Types:

Clinical trial
Multicenter study
Randomized controlled trial
PMID: 10440462, UI: 99367074




Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.


Start a new thread

Google www
Search options and examples
[amazon] for

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:JohnB thread:14073